Another Peer-reviewed Publication for GTG

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test.

Highlights:
⦁ Pancreatic cancer has a very high mortality rate, approximately 76%1 of those diagnosed will die within 1 year. The five-year survival rate is only 9%2.

⦁ GeneType’s Pancreatic Cancer risk assessment test showed a nearly 50% improvement to the traditional clinical risk score in identifying patients at a high risk of developing pancreatic cancer.

⦁ GeneType for Pancreatic Cancer will lead to a significant improvement to the number of pancreatic cancers being discovered earlier. When identified early, surgical intervention can save lives.

⦁ The study evaluated close to 380,000 adults aged 40 to 69 years from the UK Biobank, identifying 851 incident cases of pancreatic cancer, providing a very powerful validation of the geneType model.

⦁ Identifying those at-risk will enable doctors and their patients to increase surveillance and be proactive in their efforts to prevent the development of cancer.

The paper entitled “Predicting 10-year risk of pancreatic cancer using a combined genetic and clinical model” was published in the journal Gastro Hep Advances by GTG’s scientific team...

GTG’s CEO, Simon Morriss added, “We are proud to be able to offer this doctor prescribed risk assessment test, as we believe it can lead to significant improvement to the survival rate of such a dreadful disease.”

Compared to a traditional clinical risk score, geneType for pancreatic cancer showed nearly a 50% improvement in identifying patients at a high risk of developing pancreatic cancer—these adults had 4-times the population risk.

https://finance.yahoo.com/news/genetype-predicting-risk-pancreatic-cancer-123000091.html

Another Peer-reviewed Publication - they're racking 'em up!
Somethings got to work sometime...
**Where are the US Payer Pilot studies, -as promised by CEO months ago..!
SP a Shocker.

GLA.
.